Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 276 to 300 of 325

Guidance and quality standards awaiting development
Title	Type
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tinnitus	Quality standard
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]	Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217	Technology appraisal guidance
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683	Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)	Technology appraisal guidance
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845	Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]	Technology appraisal guidance
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910	Technology appraisal guidance
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]	Technology appraisal guidance
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance

Results per page

10
25
50
All